利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

57 条记录 (耗时 0.027 秒)

    Method for treating pain
    3.
    发明授权
    Method for treating pain 失效
    治疗疼痛的方法

    公开(公告)号：US06881725B2

    公开(公告)日：2005-04-19

    申请号：US10355699

    申请日：2003-01-31

    申请人： Benjamin R. Yerxa ,  Ward M. Peterson ,  Christopher S. Crean

    发明人： Benjamin R. Yerxa ,  Ward M. Peterson ,  Christopher S. Crean

    IPC分类号： C07H19/20 ,  A61K31/675 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/7084 ,  A61P23/00 ,  A61P25/04 ,  A61P25/06 ,  A61P29/00 ,  C07H19/207 ,  C07H21/00 ,  A61K31/70

    CPC分类号： A61K31/7076 ,  A61K31/675 ,  A61K31/7072 ,  A61K31/7084 ,  Y10S514/851

    摘要： The present invention is directed to a method of treating pain. The method comprises administering to a subject a pharmaceutical composition comprising an effective amount of a P2X receptor antagonist. The methods of the present invention are useful in reducing pain, such as traumatic pain, neuropathic pain, organ pain and pain associated with diseases. The P2X receptor antagonists particularly useful for this invention are mononucleoside polyphosphate derivatives or dinucleoside polyphosphate derivatives of general Formula I. The compounds of the present method can be used alone to treat pain. The compounds of the present method can also be used in conjunction with other therapeutic agents or adjunctive therapies commonly used to treat pain, thus enhancing the overall pain-reducing effect in a subject in need of such treatment.

    摘要翻译： 本发明涉及治疗疼痛的方法。 该方法包括向受试者施用包含有效量的P2X受体拮抗剂的药物组合物。 本发明的方法可用于减轻疼痛，例如创伤性疼痛，神经性疼痛，器官疼痛和与疾病相关的疼痛。 特别可用于本发明的P2X受体拮抗剂是通式I的单核苷多磷酸衍生物或二核苷多磷酸衍生物。本发明方法的化合物可单独用于治疗疼痛。 本发明方法的化合物还可以与通常用于治疗疼痛的其它治疗剂或辅助疗法结合使用，从而增强需要这种治疗的受试者的整体疼痛减轻作用。

    P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis
    4.
    发明授权
    P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating sinusitis 有权
    用于治疗鼻窦炎的P1-（2'-脱氧胞苷5' - ）P4-（尿苷5' - ）四磷酸盐，四（碱金属）盐）

    公开(公告)号：US08008274B2

    公开(公告)日：2011-08-30

    申请号：US12436679

    申请日：2009-05-06

    申请人： Benjamin R. Yerxa ,  Ward M. Peterson ,  Janet L. Rideout ,  William Pendergast

    发明人： Benjamin R. Yerxa ,  Ward M. Peterson ,  Janet L. Rideout ,  William Pendergast

    IPC分类号： A61K31/7072 ,  C07H19/10

    CPC分类号： C07H19/10 ,  A61K31/7072 ,  A61K31/7084 ,  C07H19/04 ,  C07H19/20 ,  C07H21/00 ,  Y10S514/851

    摘要： The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The present invention also provides a method of treating cystic fibrosis. The present invention also provides a method of treating sinusitis. The present invention further provides P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.

    摘要翻译： 本发明提供治疗水肿性视网膜病变的方法。 该方法包括施用包含水解抗性P2Y受体激动剂的药物制剂，以刺激从视网膜下和视网膜空间中除去病理性外来流体，从而减少与视网膜脱离和视网膜水肿相关的所述流体的积聚。 P2Y受体激动剂可以与通常用于治疗水肿性视网膜疾病的治疗剂和辅助剂一起施用。 本发明还提供治疗囊性纤维化的方法。 本发明还提供治疗鼻窦炎的方法。 本发明还提供了P1-（2'-脱氧胞苷5' - ）P4-（尿苷5'-）四磷酸盐，四钠（碱金属）盐，例如四钠，四锂，四钾和混合（四碱金属）盐 。 本发明还提供了药学上可接受的载体中包含P1-（2'-脱氧胞苷5' - ）P4-（尿苷5' - ）四磷酸盐，四 - （碱金属盐）的药物制剂。

    P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS
    5.
    发明申请
    P1-(2'-DEOXYCYTIDINE 5'-)P4-(URIDINE 5'-)TETRAPHOSPHATE, TETRA-(ALKALI METAL) SALT, FOR TREATING DISORDERS 有权
    P1-（2'-DEOXYCYTIDINE 5' - ）P4-（URIDINE 5' - ）TETRAPHOSPHATE，TETRA-（ALKALI METAL）SALT，用于治疗疾病

    公开(公告)号：US20090306010A1

    公开(公告)日：2009-12-10

    申请号：US12436679

    申请日：2009-05-06

    申请人： Benjamin R. Yerxa ,  Ward M. Peterson ,  Janet L. Rideout ,  William Pendergast

    发明人： Benjamin R. Yerxa ,  Ward M. Peterson ,  Janet L. Rideout ,  William Pendergast

    IPC分类号： A61K31/7072 ,  A61P11/00

    CPC分类号： C07H19/10 ,  A61K31/7072 ,  A61K31/7084 ,  C07H19/04 ,  C07H19/20 ,  C07H21/00 ,  Y10S514/851

    摘要： The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The present invention also provides a method of treating cystic fibrosis. The present invention also provides a method of treating sinusitis. The present invention further provides P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.

    摘要翻译： 本发明提供治疗水肿性视网膜病变的方法。 该方法包括施用包含水解抗性P2Y受体激动剂的药物制剂，以刺激从视网膜下和视网膜空间中除去病理性外来流体，从而减少与视网膜脱离和视网膜水肿相关的所述流体的积聚。 P2Y受体激动剂可以与通常用于治疗水肿性视网膜疾病的治疗剂和辅助剂一起施用。 本发明还提供治疗囊性纤维化的方法。 本发明还提供治疗鼻窦炎的方法。 本发明还提供了P1-（2'-脱氧胞苷5' - ）P4-（尿苷5'-）四磷酸盐，四钠（碱金属）盐，例如四钠，四锂，四钾和混合（四碱金属）盐 。 本发明还提供了药学上可接受的载体中包含P1-（2'-脱氧胞苷5' - ）P4-（尿苷5' - ）四磷酸盐，四 - （碱金属盐）的药物制剂。

    Method for treating or preventing inflammatory diseases
    7.
    发明授权
    Method for treating or preventing inflammatory diseases 失效
    治疗或预防炎性疾病的方法

    公开(公告)号：US07256183B2

    公开(公告)日：2007-08-14

    申请号：US10290213

    申请日：2002-11-06

    申请人： Ward M. Peterson ,  Benjamin R. Yerxa

    发明人： Ward M. Peterson ,  Benjamin R. Yerxa

    IPC分类号： A01N43/04 ,  A61K31/70

    CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K31/7084 ,  A61K2300/00

    摘要： The present invention provides a method of preventing or treating an inflammatory disease, including but not limited to, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, inflammatory bowel disease, inflammatory collagen vascular diseases, glomerulonephritis, inflammatory skin diseases, and sarcoidosis. The method comprises administrating to a subject a pharmaceutical formulation comprising a nucleotide receptor agonist, such as nucleoside diphosphate, nucleoside triphosphate, or dinucleoside polyphosphate, according to general formula Ia, Ib, IIa, IIb, or III. Preferred indications of the present invention are perennial allergic rhinitis, seasonal allergic rhinitis, infectious allergic rhinitis, and allergic conjunctivitis.

    摘要翻译： 本发明提供一种预防或治疗炎性疾病的方法，包括但不限于鼻窦炎，鼻炎，结膜炎，哮喘，皮炎，炎性肠病，炎性胶原血管疾病，肾小球性肾炎，炎性皮肤病和结节病。 该方法包括根据通式Ia，Ib，IIa，IIb或III向受试者施用包含核苷酸受体激动剂如二磷酸核苷，核苷三磷酸或二核苷多磷酸的药物制剂。 本发明的优选适应症是常年性过敏性鼻炎，季节性过敏性鼻炎，感染性过敏性鼻炎和过敏性结膜炎。

    Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
    9.
    发明授权
    Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema 有权
    使用某些二核苷酸刺激视网膜脱离和视网膜水肿中的流体去除

    公开(公告)号：US06596725B2

    公开(公告)日：2003-07-22

    申请号：US09774752

    申请日：2001-01-30

    申请人： Ward M. Peterson ,  Benjamin R. Yerxa

    发明人： Ward M. Peterson ,  Benjamin R. Yerxa

    IPC分类号： A61K900

    CPC分类号： A61K31/7084 ,  C07H19/04 ,  C07H19/20 ,  C07H21/00

    摘要： The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist may be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The pharmaceutical composition useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compounds.

    摘要翻译： 本发明提供治疗水肿性视网膜病变的方法。 该方法包括施用P2Y受体激动剂以刺激从视网膜下和视网膜空间中除去病理性外来流体，从而减少与视网膜脱离和视网膜水肿相关的所述流体的积聚。 P2Y受体激动剂可以与通常用于治疗水肿性视网膜病症的治疗剂和佐剂一起施用。 可用于本发明的药物组合物包含具有增强的细胞外水解抗性的P2Y受体激动剂，例如二核苷多磷酸盐化合物。

    P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis
    10.
    发明授权
    P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis 有权
    P1-（2'-脱氧胞苷5' - ）P4-（尿苷5' - ）四磷酸盐，四（碱金属盐），用于治疗囊性纤维化

    公开(公告)号：US07531525B2

    公开(公告)日：2009-05-12

    申请号：US11690385

    申请日：2007-03-23

    申请人： Benjamin R. Yerxa ,  Ward M. Peterson ,  Janet L. Rideout ,  William Pendergast

    发明人： Benjamin R. Yerxa ,  Ward M. Peterson ,  Janet L. Rideout ,  William Pendergast

    IPC分类号： A61K31/7072 ,  C07H19/10

    CPC分类号： C07H19/10 ,  A61K31/7072 ,  A61K31/7084 ,  C07H19/04 ,  C07H19/20 ,  C07H21/00 ,  Y10S514/851

    摘要： The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The present invention also provides a method of treating cystic fibrosis. The present invention further provides P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-) tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-) tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.

    摘要翻译： 本发明提供治疗水肿性视网膜病变的方法。 该方法包括施用包含水解抗性P2Y受体激动剂的药物制剂，以刺激从视网膜下和视网膜空间中除去病理性外来流体，从而减少与视网膜脱离和视网膜水肿相关的所述流体的积聚。 P2Y受体激动剂可以与通常用于治疗水肿性视网膜疾病的治疗剂和辅助剂一起施用。 本发明还提供治疗囊性纤维化的方法。 本发明还提供了P1-（2'-脱氧胞苷5' - ）P4-（尿苷5'-）四磷酸盐，四钠（碱金属）盐，例如四钠，四锂，四钾和混合（四碱金属）盐 。 本发明还提供了药学上可接受的载体中包含P1-（2'-脱氧胞苷5' - ）P4-（尿苷5'-）四磷酸盐，四 - （碱金属盐）的药物制剂。